Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
The defining molecular feature of Ewing sarcoma is
2020-10-01

The defining molecular feature of Ewing sarcoma is the characteristic EWSR1/ETS fusion protein, most commonly involving EWSR1 and FLI1 (Delattre et al., 1992, May et al., 1993). EWS–FLI1 causes global changes in gene expression both by directly regulating gene expression and by causing changes in ch
-
Hinokitiol has versatile abilities as anticancer antimicrobi
2020-10-01

Hinokitiol has versatile abilities as anticancer, antimicrobial and molecule transport agents and appears to have no developmental toxicity or carcinogenic effects (Imai et al., 2006b). For anticancer activities, it causes apoptosis and x04 australia arrest in many different types of cancers, such
-
Further modifications on the position of compound
2020-10-01

Further modifications on the 8-position of compound led to compound 4 (8-pCPT-2′--Me-cAMP, a.k.a. 007, ), which is a potent (half-maximal activation of EPAC1 at 2.2µM) and selective (about 100-fold EPAC/PKA selectivity) EPAC agonist. Since the discovery of compound , it has been widely used as a po
-
br Results br Discussion The process by which
2020-09-30

Results Discussion The process by which MBCs differentiate from GC B cell precursors remains mostly uncharacterized, in large part because of the uncertainty surrounding the nature of the precursor BMS 777607 australia within the GC. The identification here of a distinct subset of GC B cells,
-
br EBV BILF A Virus Encoded TM Receptor with
2020-09-30

EBV-BILF1—A Virus-Encoded 7TM Receptor with Immune Evasive Functions The EBV-encoded BILF1 receptor (EBV-BILF1) is thought to be implicated in the immune evasion strategy of EBV.56, 61, 62 This orphan 7TM receptor is expressed at significant levels during the early lytic phase of the virus infect
-
Downregulation of tumor suppressors is a major factor that
2020-09-30

Downregulation of tumor suppressors is a major factor that leads to tumorigenesis. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), a common tumor suppressor, the Telatinib of which is often downregulated or even absent in the majority of human cancers, functions as a phosphatase to d
-
The differences between ground and transition
2020-09-30

The differences between ground and transition state properties are exemplified by a comparison of our human–yeast results with those of a structural study of possible differences in ubiquitin-Uba-1 binding in yeast (known structure) with human (simulated in [12]). Their discussion focuses on Ubiquit
-
br Cyclin dependent kinases control more than cell cycle
2020-09-29

Cyclin-dependent kinases control more than cell cycle CDKs’ roles conducting the concert of NU 1025 was first revealed in the context of the tumor suppressor Rb, phosphorylation of which by CDK4 or CDK6 inactivates it loosing the transcription factor E2F [1], [12], [15]. Discovery of other cycli
-
Compound A and Compound B Fig were found in
2020-09-29

Compound A and Compound B (Fig. 4) were found in our in vitro screening assays and have similar CRF1 receptor in vitro profiles (Table 1). When binding was investigated using [125I]-CRF in ex vivo assay, Compound A inhibited binding of [125I]-CRF both in the frontal cortex and the pituitary; however
-
The aim of this study
2020-09-29

The aim of this study was to use molecular methods to characterise C. difficile isolates circulating in the Czech Republic from 2013 to 2015. Material and methods Discussion During a three-year period (2013–2015) a total of 32 hospitals voluntarily participated in this project, but only 11 ho
-
Next our exploration shifted to modifications at
2020-09-29

Next, our exploration shifted to modifications at the lateral chain of the benzoquinone nucleus (SAR 2). Considering that the CK2 inhibitory activity is favoured by the presence of the -Ph-4-NO2 (SAR 1), the subsequent analogues were investigated with this moiety retained. The influence of the side
-
br Results and discussion The results and
2020-09-28

Results and discussion The results and subgroup analysis of cholesterol and NCS from the both surveys are listed in Table 2 and shown in Fig. 1, A1 to E2. Common discussion Unlikely to the other NCS assays, a target value for cholesterol could be reported in the present survey. For NCS assays
-
We analyzed whether HaCaT cells treated with
2020-09-28

We analyzed whether HaCaT Amphotericin B treated with PLD can alter the expression of genes involved in DNA damage response. Key DNA damage cues activate the sensory DNA-PK/ATM/ATR kinases, which relay two parallel cascades that ultimately serve to inactivate the Cyclin B-cdc2 complex. The protein
-
In brief while previous studies have evaluated the individua
2020-09-28

In brief, while previous studies have evaluated the individual roles of VDR and ER signaling pathways in breast cancer, in the present study we performed an in silico approach for comparative evaluation of these pathways. Considering the complex interaction networks in the context of cancer, such co
-
Current therapeutic protocols in OS and ES
2020-09-28

Current therapeutic protocols in OS and ES consist of neoadjuvant chemotherapy and local surgical resection, followed by adjuvant chemotherapy. These treatments lead to a 70% overall survival for localized disease but can decrease to 15% in case of metastasis. With CS being resistant to conventional
16335 records 793/1089 page Previous Next First page 上5页 791792793794795 下5页 Last page